West Pharmaceutical Reports Strong Q4 Earnings, Surpassing Expectations

EXTON, Pa. - West Pharmaceutical Services Inc. (WST) announced its fourth-quarter financial results on Thursday, revealing a rise in both profits and revenue.

The company reported a net income of $130.1 million, or $1.78 per share. When excluding restructuring costs, earnings came in at $1.82 per share, surpassing analysts' expectations. The consensus estimate of five analysts surveyed by Zacks Investment Research was $1.75 per share.

Revenue for the period reached $748.8 million, also exceeding Street forecasts. Four analysts polled by Zacks had projected revenue of $739.6 million.

For the full year, West Pharmaceutical reported a profit of $492.7 million or $6.69 per share. Annual revenue reached $2.89 billion.

Looking ahead, the company anticipates full-year earnings in the range of $6 to $6.20 per share, with projected revenue between $2.88 billion and $2.91 billion.

Key Metrics:

* Q4 2023 Net Income: $130.1 million
* Q4 2023 EPS (adjusted): $1.82
* Q4 2023 Revenue: $748.8 million
* Full-Year 2023 Net Income: $492.7 million
* Full-Year 2023 EPS: $6.69
* Full-Year 2023 Revenue: $2.89 billion

This financial update was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access the Zacks stock report on WST at https://www.zacks.com/ap/WST.